Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,017.70 -7.58 (-0.74%)
Streaming Delayed Price Updated: 10:43 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
News headline image
Is the Vanguard S&P 500 Index Fund ETF a Buy Now? ↗
Via The Motley Fool
Topics ETFs Economy Government
News headline image
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
News headline image
$1,000 Invested in VUG Could Turn Into $50,000 ↗
Via The Motley Fool
Topics ETFs Economy
News headline image
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly) ↗
Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
News headline image
Which Stock Will Dominate the Weight Management Market Through 2030? ↗
Via The Motley Fool
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs ↗
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations. 
Via Benzinga
News headline image
GLP-1 Showdown In India: Eli Lilly’s Mounjaro Pen Approved Just Days After Novo’s Wegovy Launch ↗
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry. 
Via Stocktwits
Topics Intellectual Property
News headline image
5 Biotech Stocks with Highly Anticipated Pending Results ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Why This Weight Loss Drug Company's Stock Surged Today ↗
Via The Motley Fool
News headline image
3 Growth Stocks I'm Loading Up On ↗
Via The Motley Fool
Topics Artificial Intelligence Government
News headline image
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the... 
Via StockStory
Topics Earnings World Trade
News headline image
Why Shares in Novo Nordisk Lost Weight Today ↗
Via The Motley Fool
News headline image
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows ↗
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years. 
Via Benzinga
News headline image
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity ↗
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss. 
Via Investor's Business Daily
News headline image
What's Going On With Viking Therapeutics Stock On Wednesday? ↗
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
Tesla's Robotaxi Rollout ↗
Via The Motley Fool
Topics Stocks
News headline image
7 Space Stocks I'd Buy Without Hesitation ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Eli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s Sold ↗
Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more data is needed. 
Via Stocktwits
News headline image
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly ↗
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio. 
Via Benzinga
News headline image
New AI Rollouts Signal Shift From Hype to Healthcare Reality
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:LLY),(NASDAQ:PLTR),(NYSE:PHG),(NASDAQ:WAY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’ ↗
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically... 
Via Stocktwits
News headline image
Amgen Expands Development Plans For Highly Anticipated Obesity Drug ↗
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies. 
Via Investor's Business Daily
News headline image
Why Novo Nordisk Stock Is Sinking Today ↗
Via The Motley Fool
Topics Stocks Supply Chain
News headline image
IWF Is a Great Choice for Most, But I Like VUG ETF Better ↗
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern ↗
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals. 
Via Benzinga
News headline image
Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns ↗
Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects. 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.